Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05482464 · ClinicalTrials.gov registry record · NA
Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome
A NA study of Inflammatory Bowel Syndrome, sponsored by Oregon State University.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05482464 is a NA study of Inflammatory Bowel Syndrome that has completed, run by Oregon State University. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05482464, a NA study of Inflammatory Bowel Syndrome, has completed, sponsored by Oregon State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Casein glycomacropeptide (CGMP)
Study Locations (1)
Oregon
- Milam Hall, Room 001 - Corvallis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2024-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05482464
The ClinicalTrials.gov registry entry for NCT05482464 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon State University, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Inflammatory Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Casein glycomacropeptide (CGMP) is the first listed.
NCT05482464 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT05482464 about?
NCT05482464 is a clinical study titled "Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome". This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).
What is the current status of trial NCT05482464?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2022-01-01. Estimated completion is 2024-09-01.
What conditions does trial NCT05482464 study?
This clinical trial studies the following conditions: Inflammatory Bowel Syndrome.
What interventions are being tested in trial NCT05482464?
The interventions under investigation include: Casein glycomacropeptide (CGMP) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05482464?
This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05482464 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.